Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-22

Clinical Trial Update: Pharmacokinetics of BAF312 in Patients With Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of BAF312 in patients with hepatic impairment completed; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BAF312 (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hepatic Impairment | Phase 1 | Status: COMPLETED | Results posted: 2014-12-22